Amgen announces European approval of Prolia Amgen Inc.

‘By targeting RANK Ligand, Prolia provides an innovative new strategy that helps reduce fracture risk.’ ‘The approval of Prolia in europe is great news for patients as it is the first and only product approved in Europe for the treating bone loss associated with hormone ablation in guys with prostate cancers at increased risk of fractures,’ said Professor Bertrand Tombal, chairman of the division of urology and associate professor of physiology at the Universite catholique de Louvain , Cliniques universitaires Saint-Luc, Brussels, Belgium.Bristol-Myers Squibb Company Reviews Financial Results Bristol-Myers Squibb Organization reported financial results for the third quarter and nine weeks ended September 30, 2007 and updated earnings guidance for the full year. The company posted third quarter 2007 net sales of $5.1 billion, an increase of 22 percent over the same period in 2006. Bristol-Myers Squibb reported third one fourth 2007 net income of $858 million, or $0.43 per diluted share, under U.S.